You are here

Our science / Clinical Trials / Find a Trial / NCT00488397

Tigecycline In-Vitro Surveillance Study In Taiwan

Back to Search Print Save as PDF Bookmark Trial

NCT00488397

Last updated on December 6, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Taipei, Taiwan, 100 China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Community Acquired Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Clinically relevant causative isolate (no duplicates) - The isolate must meet the
laboratory criteria of "significant pathogen" and be considered the "probable
causative agent" of a hospital or community acquired infection.

- Sources - All body sites are acceptable clinical sources for isolates to be included
in this study (Intra-abdominal infection, tracheal secretion/bronchoalveolar lavage,
blood culture, wound smear). However, no more than 10 % of all isolates can come from
urine cultures.

- Within study group - Only isolates defined by the protocol are to be included.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Limited isolates from sources - No more than 10 % of all isolates from this study will
be derived from urine cultures.

- No banked or stored isolates.

- No duplicate isolates - Only one isolate per patient is permitted.

- Outside study group - Any isolate other than those defined by protocol.

NCT00488397
Pfizer
Completed
Tigecycline In-Vitro Surveillance Study In Taiwan

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Cryptococcal Meningitis, HIV Infections
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
NCT00002077
All Genders
18+
Years
Multiple Sites
Bacterial Infections, Gram-Positive Bacterial Infections, Bacteremia
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
NCT00037050
All Genders
Bacterial Infections
Tazocin Intervention Study
NCT00478855
All Genders
18+
Years
Peking,
Pneumococcal Infections
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India
NCT00452790
All Genders
0+
Years
Multiple Sites
Tigecycline In-Vitro Surveillance Study In Taiwan
Tigecycline In-Vitro Surveillance Study In Taiwan
In-vitro surveillance study of tigecycline (Tygacil) in Taiwan.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
hospital or community acquired infection
Community Acquired Infections
Other: In-vitro testing
This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
1
Intervention: Other: In-vitro testing
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
7902
February 2011
February 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinically relevant causative isolate (no duplicates) - The isolate must meet the laboratory criteria of "significant pathogen" and be considered the "probable causative agent" of a hospital or community acquired infection.
  • Sources - All body sites are acceptable clinical sources for isolates to be included in this study (Intra-abdominal infection, tracheal secretion/bronchoalveolar lavage, blood culture, wound smear). However, no more than 10 % of all isolates can come from urine cultures.
  • Within study group - Only isolates defined by the protocol are to be included.

Exclusion Criteria:

  • Limited isolates from sources - No more than 10 % of all isolates from this study will be derived from urine cultures.
  • No banked or stored isolates.
  • No duplicate isolates - Only one isolate per patient is permitted.
  • Outside study group - Any isolate other than those defined by protocol.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
China
Taiwan
 
NCT00488397
3074A1-102091
B1811055 ( Other Identifier: Pfizer )
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
March 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now